Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2019

View Archived Issues

DNA damage repair protein Mus81 promotes migration of gastric cancer through regulation of ZEB1

TWEAK/Fn14 is upregulated in Crohn's disease and has a key pathogenic role in ileitis mouse models

Xeris initiates dosing in phase II study of fixed-ratio coformulation of pramlintide and insulin

A pancreatic (pro)enzyme mixture shows high efficacy against human pancreatic cancer stem cells

CAFs 'educated' by GoF p53-mutant pancreatic cancer cells promote metastasis and chemoresistance

Novel glomerulus-on-a-chip for renal disease modeling and drug testing

Boehringer and Inflammasome partner to develop novel therapies for retinal diseases

CStone announces clinical data for CS-1001, CS-1002 and CS-1003

FDA approves Pifeltro and Delstrigo for virologically suppressed adults with HIV-1 infection

Phase I data presented from the phase I/II STERIMGLI trial of durvalumab plus hFSRT

Rottapharm Biotech presents CR-13626, an oral tyrosine kinase inhibitor for the treatment of GBM

Karyopharm presents promising phase II safety and efficacy data for selinexor in rGBM

Lenti-D demonstrates the ability to stabilize neurologic disease progression in phase II/III study

Novartis discovers new endonucleases inhibitors

Reaction Biology Corp. describes HDAC/SIRT inhibitors

U.S. Department of Defense awards research grant to Novan

New PD-1 inhibitors disclosed by Bristol-Myers Squibb

Finding a balance in treating diabetic kidney damage

Beijing Scitech-Mq Pharmaceuticals patents wild-type EGFR, EGFR T790M mutant and HER2 inhibitors

DeNovaMed identifies bacterial acyl carrier protein synthase inhibitors

GenSight reports week 96 data from phase III RESCUE trial of GS-010 in LHON

FDA approves Rybelsus for type 2 diabetes

Immune responses, tumor reductions observed with Bria-IMT and pembrolizumab in phase I/IIa study

Phase IIa study assesses efficacy of vivax malaria vaccines ChAd63 PvDBP and MVA PvDBP

Syndax initiates phase I/II study of SNDX-5613 in relapsed or refractory leukemias

Crysvita approved in Japan for FGF-23-related hypophosphatemic rickets and osteomalacia